Patents Assigned to Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
  • Method of treatment of breast cancers over-expressing the SHP2 signature genes
    Patent number: 9181553
    Abstract: A method for treating breast cancer in a subject having a breast cancer over-expressing the “SHP2 signature” genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2).
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: November 10, 2015
    Assignee: NOVARTIS FORSCHUNGSSTIFTUNG ZWEIGNIEDERLASSUNG FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Mohamed Bentires-Alj, Nicola Aceto, Michael Stadler
  • Use of protease nexin 1 inhibitors to reduce metastasis
    Patent number: 8933212
    Abstract: The present invention relates to a method of inhibiting metastasis comprising the administration of an inhibitor of protease nexin-1 (PN-1), characterized in that said inhibitor is administered at a therapeutical dosage that does not completely inhibit the expression and/or activity of PN-1.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 13, 2015
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Bérengère Fayard, Denis Monard
  • Teneurin and cancer
    Patent number: 8642280
    Abstract: The present invention relates to a method for treating cancer, for instance brain tumors, in a subject by inhibiting a teneurin by administering to said subject a therapeutically effective amount of a modulator of said teneurin, for example a specific antibody or a siRNA. The present invention also encompasses methods of diagnosing cancer by measuring levels of teneurin.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: February 4, 2014
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Ruth Chiquet-Ehrismann, Daniela Kenzelmann Bro{hacek over (z)}
  • Genetic vasectomy by overexpression of PRML-EGFP fusion protein in spermatids
    Patent number: 8633348
    Abstract: The present invention provides a genetically-modified non-human animal whose somatic and germ cells contain an exogenous gene encoding a recombinant fusion protein, wherein the presence, and expression, of said recombinant fusion protein renders said genetically-modified non-human animal sterile. Tools for generating such sterile genetically-modified non-human animal as well as methods of use thereof are also provided.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: January 21, 2014
    Assignees: Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute for Biomedical Research, Universität Zürich
    Inventors: Pawel Pelczar, Thorsten Buch, Antoine Peters
  • Purified PKB Ser 473 kinase and uses thereof
    Patent number: 7794995
    Abstract: This invention provides purified PKB Ser 473 kinase and methods of purifying it. The methods involve the use of several sequential steps, including subcellular fractionation to isolate a plasma membrane fraction and the use of gel filtration or chromatography that separates molecules according to their size or affinity.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: September 14, 2010
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Jianhua Feng, Brian A Hemmings, Michelle M Hill
  • Tumour suppressor and uses thereof
    Patent number: 7396920
    Abstract: A human protein (designated Carboxy-terminal Modulating protein, CTMP) is described and is identified as having tumour suppressor properties. CTMP has been shown to interact with protein kinase B and inhibit protein kinase B activity, establishing its importance in the protein kinase B signalling pathway.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: July 8, 2008
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Brian A Hemmings, Sauveur-Michel Maira
  • Protease-activated receptor (par) modulator assays
    Patent number: 7148018
    Abstract: There is provided a method of identifying a PAR cleaving molecule comprising the steps of: (a) providing an immobilized PAR cleavage peptide linked to a reporter molecule; (b) contacting the immobilized PAR cleavage peptide with a PAR cleaving molecule; and (c) detecting release of the reporter molecule.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: December 12, 2006
    Assignee: Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
    Inventors: Ludger Altrogge, Denis Monard